Farther Finance Advisors LLC Grows Holdings in Moderna, Inc. $MRNA

Farther Finance Advisors LLC increased its position in Moderna, Inc. (NASDAQ:MRNA) by 34.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,783 shares of the company’s stock after acquiring an additional 1,238 shares during the quarter. Farther Finance Advisors LLC’s holdings in Moderna were worth $132,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. S Bank Fund Management Ltd purchased a new position in shares of Moderna in the first quarter valued at $25,000. SVB Wealth LLC bought a new stake in Moderna in the first quarter worth $28,000. CX Institutional lifted its position in shares of Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company’s stock worth $29,000 after purchasing an additional 949 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of Moderna during the first quarter worth $30,000. Finally, Sentry Investment Management LLC bought a new stake in shares of Moderna during the first quarter worth $31,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of MRNA stock opened at $28.37 on Friday. The company has a market cap of $11.04 billion, a price-to-earnings ratio of -3.77 and a beta of 2.01. The stock has a 50 day simple moving average of $26.41 and a 200-day simple moving average of $27.44. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $62.97.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million during the quarter, compared to analysts’ expectations of $116.26 million. During the same period in the previous year, the business earned ($3.33) earnings per share. The firm’s revenue for the quarter was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

MRNA has been the topic of several research reports. Barclays cut their price target on Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a research note on Monday, August 4th. Citigroup started coverage on Moderna in a report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price target for the company. Leerink Partners dropped their target price on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research report on Friday, August 22nd. JPMorgan Chase & Co. set a $26.00 target price on Moderna in a research report on Friday, August 1st. Finally, Cowen started coverage on Moderna in a report on Sunday, July 13th. They issued a “hold” rating for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $41.81.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.